Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health (NIH)
Up to $1,500,000 in direct costs per year
Project period limited to five years for Early Stage projects and four years for Late Stage projects
To support the development of novel drug candidates for Alzheimer's disease
Encourage biomedical, social, and behavioral research related to aging and Alzheimer's disease
Researchers in the field of Alzheimer's disease
Patients affected by Alzheimer's disease
National Institutes of Health (NIH)
Cooperative Agreements (U01)
Recurring funding opportunity
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (including those with and without 501(c)(3) status)
For-Profit Organizations
Small Businesses
Local, State, County, and City Governments
Indian/Native American Tribal Governments
Federal Agencies
U.S. organizations only; foreign organizations are not eligible
Development of drug candidates for Alzheimer's disease
Pre-clinical and early-stage clinical development
Therapeutic development activities including medicinal chemistry, pharmacokinetics, and initial Phase I clinical testing
Experience in drug development and clinical trials
Application budgets are limited to $1,500,000 in direct costs per year
Application due date: June 5, 2027
Compliance with NIH guidance on rigor and reproducibility
Follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide